Sort by
Previous Page Page 2 of 19 Next Page
  1. Research

    Proportion of dementia in Australia explained by common modifiable risk factors

    At present, dementia has no known cure. Interventions to delay onset and reduce prevalence of the disease are therefore focused on risk factor reduction. Previous population attributable risk estimates for wes...

    Kimberly Ashby-Mitchell, Richard Burns, Jonathan Shaw and Kaarin J. Anstey

    Alzheimer's Research & Therapy 2017 9:11

    Published on: 17 February 2017

  2. Research

    The effects of different familial Alzheimer’s disease mutations on APP processing in vivo

    Disturbed amyloid precursor protein (APP) processing is considered to be central to the pathogenesis of Alzheimer’s disease (AD). The autosomal dominant form of the disease, familial AD (FAD), may serve as a m...

    Steinunn Thordardottir, Anne Kinhult Ståhlbom, Ove Almkvist, Håkan Thonberg, Maria Eriksdotter, Henrik Zetterberg, Kaj Blennow and Caroline Graff

    Alzheimer's Research & Therapy 2017 9:9

    Published on: 16 February 2017

  3. Research

    Increased dementia risk predominantly in diabetes mellitus rather than in hypertension or hyperlipidemia: a population-based cohort study

    The pathophysiology of insulin resistance-induced hypertension and hyperlipidemia might entail differences in dementia risk in cases with hypertension and hyperlipidemia without prior diabetes mellitus (DM). T...

    Yen-Chun Fan, Jung-Lung Hsu, Hong-Yi Tung, Chia-Chi Chou and Chyi-Huey Bai

    Alzheimer's Research & Therapy 2017 9:7

    Published on: 6 February 2017

  4. Research

    Interaction between personality traits and cerebrospinal fluid biomarkers of Alzheimer’s disease pathology modulates cognitive performance

    During adulthood, personality characteristics may contribute to the individual capacity to compensate the impact of developing cerebral Alzheimer’s disease (AD) pathology on cognitive impairment in later life....

    Domilė Tautvydaitė, Deepti Kukreja, Jean-Philippe Antonietti, Hugues Henry, Armin von Gunten and Julius Popp

    Alzheimer's Research & Therapy 2017 9:6

    Published on: 2 February 2017

  5. Research

    Peripheral apoE isoform levels in cognitively normal APOE ε3/ε4 individuals are associated with regional gray matter volume and cerebral glucose metabolism

    Carriers of the APOE ε4 allele are at increased risk of developing Alzheimer’s disease (AD), and have been shown to have reduced cerebral metabolic rate of glucose (CMRgl) in the same brain areas frequently affec...

    Henrietta M. Nielsen, Kewei Chen, Wendy Lee, Yinghua Chen, Robert J. Bauer, Eric Reiman, Richard Caselli and Guojun Bu

    Alzheimer's Research & Therapy 2017 9:5

    Published on: 30 January 2017

  6. Research

    A cognitive electrophysiological signature differentiates amnestic mild cognitive impairment from normal aging

    Noninvasive and effective biomarkers for early detection of amnestic mild cognitive impairment (aMCI) before measurable changes in behavioral performance remain scarce. Cognitive event-related potentials (ERPs...

    Juan Li, Lucas S. Broster, Gregory A. Jicha, Nancy B. Munro, Frederick A. Schmitt, Erin Abner, Richard Kryscio, Charles D. Smith and Yang Jiang

    Alzheimer's Research & Therapy 2017 9:3

    Published on: 19 January 2017

  7. Research

    Diagnostic impact of [18F]flutemetamol PET in early-onset dementia

    Early-onset dementia patients often present with atypical clinical symptoms, hampering an accurate clinical diagnosis. The purpose of the present study was to assess the diagnostic impact of the amyloid-positr...

    Marissa D. Zwan, Femke H. Bouwman, Elles Konijnenberg, Wiesje M. van der Flier, Adriaan A. Lammertsma, Frans R. J. Verhey, Pauline Aalten, Bart N. M. van Berckel and Philip Scheltens

    Alzheimer's Research & Therapy 2017 9:2

    Published on: 17 January 2017

  8. Research

    Tau passive immunization inhibits not only tau but also Aβ pathology

    Accumulation of hyperphosphorylated tau protein is a histopathological hallmark of Alzheimer’s disease (AD) and related tauopathies. Currently, there is no effective treatment available for these progressive n...

    Chun-ling Dai, Yunn Chyn Tung, Fei Liu, Cheng-Xin Gong and Khalid Iqbal

    Alzheimer's Research & Therapy 2017 9:1

    Published on: 10 January 2017

  9. Research

    Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology

    Hyperphosphorylation and aggregation of tau protein are the pathological hallmarks of Alzheimer’s disease and related tauopathies. We previously demonstrated that the microglial activation induces tau hyperpho...

    Nicole Maphis, Shanya Jiang, Guixiang Xu, Olga N. Kokiko-Cochran, Saktimayee M. Roy, Linda J. Van Eldik, D. Martin Watterson, Bruce T. Lamb and Kiran Bhaskar

    Alzheimer's Research & Therapy 2016 8:54

    Published on: 15 December 2016

  10. Research

    A digital enzyme-linked immunosorbent assay for ultrasensitive measurement of amyloid-β 1–42 peptide in human plasma with utility for studies of Alzheimer’s disease therapeutics

    Amyloid-β 1–42 peptide (Aβ1–42) is associated with plaque formation in the brain of patients with Alzheimer’s disease (AD). Pharmacodynamic studies of AD therapeutics that lower the concentrations of Aβ1–42 in pe...

    Linan Song, D. Richard Lachno, David Hanlon, Adam Shepro, Andreas Jeromin, Dipika Gemani, Jayne A. Talbot, Margaret M. Racke, Jeffrey L. Dage and Robert A. Dean

    Alzheimer's Research & Therapy 2016 8:58

    Published on: 15 December 2016

  11. Research

    LW-AFC, a new formula derived from Liuwei Dihuang decoction, ameliorates behavioral and pathological deterioration via modulating the neuroendocrine-immune system in PrP-hAβPPswe/PS1ΔE9 transgenic mice

    Accumulating evidence implicates the neuroendocrine immunomodulation (NIM) network in the physiopathological mechanism of Alzheimer’s disease (AD). Notably, we previously revealed that the NIM network is dysre...

    Jian-Hui Wang, Xi Lei, Xiao-Rui Cheng, Xiao-Rui Zhang, Gang Liu, Jun-Ping Cheng, Yi-Ran Xu, Ju Zeng, Wen-Xia Zhou and Yong-Xiang Zhang

    Alzheimer's Research & Therapy 2016 8:57

    Published on: 13 December 2016

  12. Research

    Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer’s disease

    According to new diagnostic guidelines for Alzheimer’s disease (AD), biomarkers enable estimation of the individual likelihood of underlying AD pathophysiology and the associated risk of progression to AD deme...

    Panagiotis Alexopoulos, Lukas Werle, Jennifer Roesler, Nathalie Thierjung, Lena Sophie Gleixner, Igor Yakushev, Nikolaos Laskaris, Stefan Wagenpfeil, Philippos Gourzis, Alexander Kurz and Robert Perneczky

    Alzheimer's Research & Therapy 2016 8:51

    Published on: 9 December 2016

  13. Research

    Brain activation in frontotemporal and Alzheimer’s dementia: a functional near-infrared spectroscopy study

    Frontotemporal dementia is an increasingly studied disease, the underlying functional impairments on a neurobiological level of which have not been fully understood. Patients with the behavioral-subtype fronto...

    Florian G. Metzger, Betti Schopp, Florian B. Haeussinger, Katja Dehnen, Matthis Synofzik, Andreas J. Fallgatter and Ann-Christine Ehlis

    Alzheimer's Research & Therapy 2016 8:56

    Published on: 8 December 2016

  14. Review

    An update on semantic dementia: genetics, imaging, and pathology

    Progressive and relatively circumscribed loss of semantic knowledge, referred to as semantic dementia (SD) which falls under the broader umbrella of frontotemporal dementia, was officially identified as a clin...

    Ramon Landin-Romero, Rachel Tan, John R. Hodges and Fiona Kumfor

    Alzheimer's Research & Therapy 2016 8:52

    Published on: 5 December 2016

  15. Research

    Angiotensin-converting enzyme 2 is reduced in Alzheimer’s disease in association with increasing amyloid-β and tau pathology

    Hyperactivity of the classical axis of the renin-angiotensin system (RAS), mediated by angiotensin II (Ang II) activation of the angiotensin II type 1 receptor (AT1R), is implicated in the pathogenesis of Alzh...

    Patrick Gavin Kehoe, Steffenny Wong, Noura AL Mulhim, Laura Elyse Palmer and J. Scott Miners

    Alzheimer's Research & Therapy 2016 8:50

    Published on: 25 November 2016

  16. Research

    Outcomes measures in a decade of dementia and mild cognitive impairment trials

    In a research study, to give a comprehensive evaluation of the impact of interventions, the outcome measures should reflect the lived experience of the condition. In dementia studies, this necessitates the use...

    Jennifer Kirsty Harrison, Anna H. Noel-Storr, Nele Demeyere, Emma L. Reynish and Terry J. Quinn

    Alzheimer's Research & Therapy 2016 8:48

    Published on: 21 November 2016

  17. Research

    The societal costs of dementia in Sweden 2012 – relevance and methodological challenges in valuing informal care

    In this study, we sought to estimate the societal cost of illness in dementia in Sweden in 2012 using different costing approaches to highlight methodological issues.

    Anders Wimo, Linus Jönsson, Laura Fratiglioni, Per Olof Sandman, Anders Gustavsson, Anders Sköldunger and Lennarth Johansson

    Alzheimer's Research & Therapy 2016 8:59

    Published on: 18 November 2016

    The Erratum to this article has been published in Alzheimer's Research & Therapy 2017 9:12

  18. Research

    Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer’s disease: post-hoc analysis of a randomized placebo-controlled study

    A large, prospective, 2-year, randomized study in patients with mild-to-moderate Alzheimer’s disease or mixed dementia demonstrated reductions in mortality and cognitive/functional decline in galantamine-treat...

    Klaus Hager, Alan S. Baseman, Jeffrey S. Nye, H. Robert Brashear, John Han, Mary Sano, Bonnie Davis and Henry M. Richards

    Alzheimer's Research & Therapy 2016 8:47

    Published on: 15 November 2016

  19. Research

    Psychological, behavioral and social effects of disclosing Alzheimer’s disease biomarkers to research participants: a systematic review

    Current Alzheimer’s disease (AD) research initiatives focus on cognitively healthy individuals with biomarkers that are associated with the development of AD. It is unclear whether biomarker results should be ...

    S. A. S. A. Bemelmans, K. Tromp, E. M. Bunnik, R. J. Milne, S. Badger, C. Brayne, M. H. Schermer and E. Richard

    Alzheimer's Research & Therapy 2016 8:46

    Published on: 10 November 2016

Previous Page Page 2 of 19 Next Page